ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos1.52 B1.54 B1.5 B1.51 B1.53 B6.09 BInvestigación y desarrollo106 M99 M91 M94 M98 M382 MBeneficio operativo483 M558 M692 M629 M535 M2.41 BTotal de ingresos no operativos-42 M-6 M-10 M-10 M-10 M-36 MGastos por intereses, netos de intereses capitalizados108 M107 M107 M107 M109 M430 MIngresos no operativos, una vez deducidos los gastos por intereses-153 M-113 M-118 M-127 M-118 M-476 MIngresos/gastos extraordinarios3 M01 M10 M-1 M10 MBeneficio antes de impuestos346 M458 M588 M526 M427 M2 BParticipación en los beneficios——————Impuestos53 M136 M168 M128 M97 M529 MParticipación minoritaria——————Otros ingresos/gastos después de impuestos-33 M-16 M-17 M-21 M-13 M-67 MBeneficio neto antes de actividades interrumpidas293 M322 M420 M398 M330 M1.47 BOperaciones suspendidas——————Beneficio neto293 M322 M420 M398 M330 M1.47 BAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas293 M322 M420 M398 M330 M1.47 BBeneficio básico por acción0.160.170.220.210.170.77Beneficio por acción diluido0.160.170.220.210.160.76Número medio de acciones ordinarias1.92 B1.91 B1.92 B1.92 B1.92 B7.67 BAcciones diluidas1.92 B1.93 B1.93 B1.92 B1.92 B7.7 BEBITDA67 M466 M594 M529 M-6 M1.58 BEBIT-83 M330 M452 M388 M-144 M1.03 BCosto de los ingresos1.59 B1.57 B1.58 B1.54 B1.64 B6.33 BOtros costes de producción——————Amortización y depreciación (flujo de caja)150 M136 M142 M141 M138 M557 M
Kenvue Inc
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.